Log in to save to my catalogue

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drosp...

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drosp...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_52e18a8935a64a1990c1d3d02be0e5ae

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime

About this item

Full title

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime

Publisher

England: BioMed Central Ltd

Journal title

BMC women's health, 2020-10, Vol.20 (1), p.218-9, Article 218

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrogenic properties. The purpose of these clinical trials with a n...

Alternative Titles

Full title

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_52e18a8935a64a1990c1d3d02be0e5ae

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_52e18a8935a64a1990c1d3d02be0e5ae

Other Identifiers

ISSN

1472-6874

E-ISSN

1472-6874

DOI

10.1186/s12905-020-01080-9

How to access this item